Search

Displaying results 5461 - 5470 of 10000 in total
  1. Drug

    TPI-ASM8

    go.drugbank.com/drugs/DB05572
    Investigational

    TPI-ASM8 was under investigation in clinical trials NCT00822861, NCT01158898, NCT00402948, and NCT00550797, all for the treatment of Asthma.

  2. Drug

    AB192

    go.drugbank.com/drugs/DB06111
    Experimental

    AB192 is a DPP IV enzymatic activity inhibitor.

  3. Drug

    Vespula maculifrons venom protein

    go.drugbank.com/drugs/DB10956
    Approved

    Vespula maculifrons venom protein is an extract of Vespula maculifrons venom. Vespula maculifrons venom protein is used in allergenic testing.

  4. Drug

    Polistes annularis venom protein

    go.drugbank.com/drugs/DB11027
    Approved

    Polistes annularis venom protein is an extract of Polistes annularis venom. Polistes annularis venom protein is used in allergenic testing.

  5. Drug

    Vespula germanica venom protein

    go.drugbank.com/drugs/DB11030
    Approved

    Vespula germanica venom protein is an extract of Vespula germanica venom. Vespula germanica venom protein is used in allergenic testing.

  6. Drug

    GLB-001

    go.drugbank.com/drugs/DB32795
    Investigational

    GLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).[L56124, L56125, L56126]

  7. Drug

    Tetrahydrofolic acid

    go.drugbank.com/drugs/DB00116
    InvestigationalNutraceutical

    It is converted into 5,10-methylenetetrahydrofolate by serine hydroxymethyltransferase. It is a soluble coenzyme in many reactions, especially in the metabolism of amino acids and nucleic acids. … Tetrahydrofolic acid is a folic acid derivative that is produced from dihydrofolic acid after conversion by dihydrofolate reductase.

  8. Drug

    Asvasiran

    go.drugbank.com/drugs/DB05638
    Investigational

    Asvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.

  9. Drug

    Inolimomab

    go.drugbank.com/drugs/DB15628
    Investigational

    It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.[A241385] … Inolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease.

  10. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230. … Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.